Dr. John Carter, MD
Rheumatology (Rheumatology Physician)
- Medicare participating
At a glance
- Medical school
- Saint Louis University School of Medicine (1996)
- Years since graduation
- 30
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 231
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1996Medical school: Saint Louis University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
FL license ME74849
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- St Josephs Hospital Tampa, FL
- Tampa General Hospital Tampa, FL
- Lakewood Ranch Medical Center Bradenton, FL
Medical groups
- American Arthritis and Rheumatology Associates LLC (65 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 231
- Services billed
- 6,145
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 277 | 173 |
| New patient office or other outpatient visit, 45-59 minutes | 24 | 24 |
| Established patient office or other outpatient visit, 20-29 minutes | 16 | 15 |
| Established patient office or other outpatient visit, 40-54 minutes | 15 | 13 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 13 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Hydroxychloroquine Sulfate Other prescribers in Tampa, FL | 348 |
| Methotrexate (methotrexate sodium) Other prescribers in Tampa, FL | 189 |
| Prednisone Other prescribers in Tampa, FL | 146 |
| Leflunomide Other prescribers in Tampa, FL | 95 |
| Enbrel Sureclick (etanercept) Other prescribers in Tampa, FL | 90 |
| Celecoxib Other prescribers in Tampa, FL | 88 |
| Gabapentin Other prescribers in Tampa, FL | 70 |
| Duloxetine Hcl Other prescribers in Tampa, FL | 65 |
| Meloxicam Other prescribers in Tampa, FL | 63 |
| Otezla (apremilast) Other prescribers in Tampa, FL | 62 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 20 companies reported 212 payments worth $25,118 in total to this clinician.
| AbbVie Inc. | $16,231 |
|---|---|
| Amgen Inc. | $6,342 |
| Ani Pharmaceuticals, Inc. | $403 |
| UCB, Inc. | $342 |
| GlaxoSmithKline, LLC. | $294 |
| Mallinckrodt Hospital Products Inc. | $294 |
| AstraZeneca Pharmaceuticals LP | $247 |
| Pfizer Inc. | $207 |
| Compensation for services other than consulting (speaking, faculty) | $20,200 |
|---|---|
| Food and Beverage | $4,815 |
| Travel and Lodging | $60.15 |
| Education | $43.25 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Jan 14, 2025 | Compensation for services other than consulting (speaking, faculty) SKYRIZI · IMMUNOLOGY | $3,000 |
| AbbVie Inc. Mar 31, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $3,000 |
| AbbVie Inc. Apr 11, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $3,000 |
| AbbVie Inc. Sep 12, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $3,000 |
| AbbVie Inc. Dec 11, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $3,000 |
| Amgen Inc. Nov 14, 2025 | Compensation for services other than consulting (speaking, faculty) OTEZLA · Inflammation | $2,400 |
| Amgen Inc. Sep 9, 2025 | Compensation for services other than consulting (speaking, faculty) OTEZLA · Inflammation | $2,400 |
| Amgen Inc. Mar 28, 2025 | Compensation for services other than consulting (speaking, faculty) OTEZLA · Inflammation | $400 |
| AbbVie Inc. Apr 2, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to CINCINNATI, OH · in-kind | $57.40 |
| AstraZeneca Pharmaceuticals LP Nov 19, 2025 | Education ENHERTU · Oncology · in-kind Company’s descriptionJournal Article | $43.25 |
All 11 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Dec 11, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $3,000 |
| AstraZeneca Pharmaceuticals LP Nov 19, 2025 | Education ENHERTU · Oncology · in-kind Company’s descriptionJournal Article | $43.25 |
| Amgen Inc. Nov 14, 2025 | Compensation for services other than consulting (speaking, faculty) OTEZLA · Inflammation | $2,400 |
| AbbVie Inc. Sep 12, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $3,000 |
| Amgen Inc. Sep 9, 2025 | Compensation for services other than consulting (speaking, faculty) OTEZLA · Inflammation | $2,400 |
| AbbVie Inc. Apr 11, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $3,000 |
| AbbVie Inc. Apr 2, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to CINCINNATI, OH · in-kind | $57.40 |
| AbbVie Inc. Apr 2, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to CINCINNATI, OH · in-kind | $2.75 |
| AbbVie Inc. Mar 31, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $3,000 |
| Amgen Inc. Mar 28, 2025 | Compensation for services other than consulting (speaking, faculty) OTEZLA · Inflammation | $400 |
| AbbVie Inc. Jan 14, 2025 | Compensation for services other than consulting (speaking, faculty) SKYRIZI · IMMUNOLOGY | $3,000 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 20 industry-funded studies in 2025, from 9 companies. The companies reported $1,117,156 in research payments for these studies, mostly to the institutions running them.
- Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patie…
Argenx US, Inc. - Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
Eli Lilly and Company · Completed · NCT06588296 - A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic…
Takeda Pharmaceuticals U.S.A., Inc. - Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
AbbVie Inc. · Recruiting · NCT06865105 - A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
AbbVie Inc. · Recruiting · NCT06972446 - A phase 4, multicenter, prospective, open-label study describing the e
GlaxoSmithKline, LLC. - A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis
Sanofi US Services Inc. · Completed · NCT06073093 - A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgren's Syndrome
Amgen Inc. - A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgrens Syndrome
Amgen Inc. - A phase 2A, single-arm study to investigate the efficacy and safety of LY3541860 in adult participants with moderately-to-severely active rheumatoid arthritis
Eli Lilly and Company
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.